Phase I/II Trial of Preoperative Radiotherapy With Concurrent Bevacizumab, Erlotinib and Capecitabine for Locally Advanced Rectal Cancer.

Trial Profile

Phase I/II Trial of Preoperative Radiotherapy With Concurrent Bevacizumab, Erlotinib and Capecitabine for Locally Advanced Rectal Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Mar 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Capecitabine
  • Indications Rectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Dec 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 05 Dec 2013 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center record.
    • 18 Nov 2013 Planned end date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top